[BurningFrog]

I expect most of the cost is regulatory.

Lighter regulation around rare "small market" diseases might save a lot of lives. And money.

[soldehierro]

> Lighter regulation around rare "small market" diseases might save a lot of lives. And money.

Orphan drugs for rare diseases are already subject to less regulation.